Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the ona domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/risezcom/public_html/cord-blood.org.uk/wp-includes/functions.php on line 6131
New Treatment Shows Promise in Eradicating Acute Myeloid Leukemia Stem Cells - Cord Blood

Cord Blood

and Stem Cell Banking

New Treatment Shows Promise in Eradicating Acute Myeloid Leukemia Stem Cells

Cell cross section

Acute myeloid leukemia (AML) is a type of blood cancer that can be challenging to treat because of leukemia stem cells (LSCs) that evade existing therapies. However, a new study has discovered a potential solution. Researchers engineered stem cells and their exosomes to specifically target and eradicate LSCs, offering hope for improved AML treatment outcomes.

The Role of LSCs in AML

LSCs are responsible for the persistence of AML and its resistance to traditional treatments. These cells have the ability to avoid senescence, a process that stops the growth of abnormal cells. Previous research has shown that inducing senescence in LSCs can lead to their elimination and improved survival for AML patients.

The Power of miR-34c-5p

Scientists discovered that miR-34c-5p, a tiny RNA molecule, plays a crucial role in promoting senescence in LSCs. In an AML mouse model, they found that increasing the levels of miR-34c-5p resulted in the elimination of LSCs and prolonged survival. However, delivering miR-34c-5p to LSCs presents challenges, as it can be easily degraded in the bloodstream and may affect normal cells.

Engineering Stem Cells and Exosomes for Targeted Delivery

To overcome these challenges, researchers engineered mesenchymal stem cells (MSCs) and their exosomes to deliver miR-34c-5p specifically to LSCs. MSCs have several advantages as drug carriers, including their ability to migrate to cancerous sites. Exosomes, a type of small vesicle, can efficiently combine with target cells and have tissue-specific targeting abilities.

Creating Targeted Exosomes

The study team modified MSCs and their exosomes to express specific proteins that enable them to home in on LSCs. They introduced a fusion protein called Lamp2b-IL3, which recognizes CD123, a receptor highly expressed in LSCs. Additionally, they incorporated HCELL, a modified form of CD44, to help the exosomes overcome the protective bone marrow niche where LSCs are located.

Promising Results in Animal Models

Using a humanized AML mouse model, the researchers tested the engineered exosomes loaded with miR-34c-5p. They found that these exosomes selectively targeted and eradicated LSCs, impeding the development of AML. The mice treated with the engineered exosomes showed increased survival rates, indicating the effectiveness of this new treatment approach.

A Step Forward in AML Treatment

This study provides valuable insights into the development of novel therapies for targeting and eliminating LSCs in AML. The engineered stem cells and exosomes show promise as an effective delivery system for miR-34c-5p and other therapeutic molecules with greater specificity. This could lead to improved outcomes for AML patients, offering hope for a future where LSCs can be effectively eradicated.